Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer
about
New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastimConcise review: Sowing the seeds of a fruitful harvest: hematopoietic stem cell mobilizationEngineering long shelf life multi-layer biologically active surfaces on microfluidic devices for point of care applicationsOncology.The efficacy of recombinant TPO in murine And nonhuman primate models for myelosuppression and stem cell transplantation.Therapeutic use of recombinant human G-CSF (rhG-CSF) in a canine model of sublethal and lethal whole-body irradiation.Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer.Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin's lymphoma.Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study.Mitoxantrone/high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin's lymphoma. A pilot study.Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma.Effect of recombinant human interleukin-3 on haematological recovery from chemotherapy-induced myelosuppression.Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer.Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.The efficacy of recombinant thrombopoietin in murine and nonhuman primate models for radiation-induced myelosuppression and stem cell transplantation.Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis.Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trialClinical applications of recombinant human colony-stimulating factors.Sweet's syndrome associated with G-CSF.The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo.Long-term exposure to retrovirally expressed granulocyte-colony-stimulating factor induces a nonneoplastic granulocytic and progenitor cell hyperplasia without tissue damage in miceThe therapeutic potential of interleukin-1 and tumor necrosis factor on hematopoietic stem cells.Role of lipegfilgrastim in the management of chemotherapy-induced neutropeniaNew perspectives in lung cancer. 4. Haematopoietic growth factors and lung cancer treatment.G-CSF: status quo and new indications.Clinical applications of granulocyte colony stimulating factor (G-CSF).Leukocyte integrin activation mediates transient neutropenia after G-CSF administration.The potential role of recombinant hematopoietic colony-stimulating factors in preventing infections in the immunocompromised hostThe colony-stimulating factors and cancer.High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancerHigh dose intensity combination chemotherapy for advanced epithelial ovarian carcinoma: results of a pilot study.High dose combination chemotherapy with ifosfamide, cyclophosphamide or cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase I/II studySerious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma.The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancerCODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.Pegfilgrastim -- rational drug design for the management of chemotherapy-induced neutropenia.Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity studyThe use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancerThe impact of colony stimulating factors on cancer chemotherapy.G-CSF and M-CSF: from molecular biology to clinical application.
P2860
Q26738509-2B92F99F-9E4C-4665-911D-ABAE7AF525FDQ26825518-A9474E2F-5E58-468A-AE2B-3C748B707F3FQ30390401-61FEA7F7-8A9E-4664-A00A-E601C820B71EQ30493410-3D53FB47-87B4-4DDC-B0F7-0F21A5B2BFB2Q33334361-85AE6DB0-9EE6-4E22-BE17-1E22147CCDC9Q33372274-E5EC0C90-A6DC-440E-AAAF-5C1738CEF1EDQ33372338-8204CFC6-7A9C-45E3-B8A2-2E45C6BCCA73Q33372727-825FDBA2-B082-45A4-AEE1-3134AC14F26BQ33373500-131C205E-4455-43B2-B40A-8C41B703D39EQ33397332-1DD88A3D-5DFD-4E9F-8CB1-14BB924036D7Q33488800-8EB252B1-5BD9-4031-9D78-31C2AC1BDEAEQ33491384-1A83A768-3955-492F-9077-4DD68A24EF39Q33496996-3FCBEE11-940C-4B24-A7BA-C4CF64BC1A02Q33497873-0BBA3705-15B0-4C8D-9DA8-056C0D0BD7F1Q33504493-3CFCEB5B-89FE-4A8B-8497-3AD8E50484C8Q33780538-A3430E78-D04F-4EA7-8A80-8B64485FE91BQ34013208-1C2350C9-399C-490B-A178-B01D317AA7CDQ34102759-6674238C-FB37-4D6E-9473-90544B4D2CF8Q34290651-0D0AC450-3F9C-43BF-9689-F6665C9E2EEDQ34323778-C606C88A-BC51-4A65-958B-86826323A9F2Q34578841-B70F3287-1B54-488F-A6EA-367C0174912FQ35196479-FD31DB07-5C34-44B5-B53A-0DF8683790C3Q35298321-D44F6D0D-2C65-4E11-A98D-9239AFC112D3Q35312342-46441DDE-07C3-49E1-891B-8F325AC6883AQ35335794-DAAE5118-A77E-4CB5-BE24-5496D6BF34F7Q35337958-ED96BA8B-C9FF-4A5E-AAF8-37DAB4B38A17Q35483752-4D61DE75-DC45-47DC-901C-B67BA4DFF7CEQ35893155-21C4BE2D-321E-461C-910E-4740C33714DAQ35936937-DEA3456B-351A-46A6-9A3E-D87B61473D06Q35976530-47E4AA71-BB44-40C2-A73D-68257515344AQ35981723-765981F2-41B8-49B5-89BC-7B436EC53533Q35983021-170F187C-02CF-4491-9F7D-B586F5B52393Q36080167-0268B865-A5D5-4CF2-9A6B-2317741AD2D3Q36080547-633FBD84-F253-49CC-BC4E-FE61BE1F8E93Q36115919-ECE4D298-57D7-4786-9A1D-B014294B8496Q36297208-03D4D7C5-83F3-48FE-AE45-EE5EE0667E6CQ36466999-E366EEB0-B57C-4521-9B7E-7D4011F3CBADQ36468076-64CC6FE0-922F-425F-8D93-679494C7662CQ36591657-DDC4B849-DE50-4DAD-969A-5C408FFF0D0AQ36616692-59A5C5C5-2D3E-4B8D-B3AF-1CBFC7065619
P2860
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
1987年论文
@zh
1987年论文
@zh-cn
name
Phase I/II study of recombinan ...... apy for small cell lung cancer
@ast
Phase I/II study of recombinan ...... apy for small cell lung cancer
@en
type
label
Phase I/II study of recombinan ...... apy for small cell lung cancer
@ast
Phase I/II study of recombinan ...... apy for small cell lung cancer
@en
prefLabel
Phase I/II study of recombinan ...... apy for small cell lung cancer
@ast
Phase I/II study of recombinan ...... apy for small cell lung cancer
@en
P2093
P2860
P356
P1476
Phase I/II study of recombinan ...... apy for small cell lung cancer
@en
P2093
Bronchud MH
Crowther D
Scarffe JH
Thatcher N
P2860
P2888
P304
P356
10.1038/BJC.1987.295
P407
P577
1987-12-01T00:00:00Z